Alnylam Pharmace. buy Piper Sandler
Start price
14.12.23
/
50%
€169.60
Target price
14.12.24
€197.08
Performance (%)
-16.51%
Price
03.05.24
€141.60
Summary
This prediction is currently active. The price of Alnylam Pharmace. has decreased since the start of the prediction. Compared to the start price this results in a performance of -16.51%. This prediction currently runs until 14.12.24. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 5.751% | 5.751% |
| iShares Core DAX® | -0.922% | -1.993% |
| iShares Nasdaq 100 | 0.371% | -0.868% |
| iShares Nikkei 225® | 2.224% | -5.187% |
| iShares S&P 500 | -0.026% | -0.918% |
Comments by Piper_Sandler for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Piper Sandler from $210.00 to $217.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat